139 related articles for article (PubMed ID: 38469811)
1. Free PEG Suppresses Anaphylaxis to PEGylated Nanomedicine in Swine.
Shen L; Li Z; Ma A; Cruz-Teran C; Talkington A; Shipley ST; Lai SK
ACS Nano; 2024 Mar; 18(12):8733-8744. PubMed ID: 38469811
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice.
McSweeney MD; Shen L; DeWalle AC; Joiner JB; Ciociola EC; Raghuwanshi D; Macauley MS; Lai SK
J Control Release; 2021 Jan; 329():774-781. PubMed ID: 33038448
[TBL] [Abstract][Full Text] [Related]
3. Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions.
Kozma GT; Mészáros T; Vashegyi I; Fülöp T; Örfi E; Dézsi L; Rosivall L; Bavli Y; Urbanics R; Mollnes TE; Barenholz Y; Szebeni J
ACS Nano; 2019 Aug; 13(8):9315-9324. PubMed ID: 31348638
[TBL] [Abstract][Full Text] [Related]
4. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.
McSweeney MD; Price LSL; Wessler T; Ciociola EC; Herity LB; Piscitelli JA; DeWalle AC; Harris TN; Chan AKP; Saw RS; Hu P; Jennette JC; Forest MG; Cao Y; Montgomery SA; Zamboni WC; Lai SK
J Control Release; 2019 Oct; 311-312():138-146. PubMed ID: 31454530
[TBL] [Abstract][Full Text] [Related]
5. Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse.
Li Z; Shen L; Ma A; Talkington A; Li Z; Nyborg AC; Bowers MS; LaMoreaux B; Livingston EW; Frank JE; Yuan H; Lai SK
Acta Biomater; 2023 Oct; 170():250-259. PubMed ID: 37659730
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines.
Chen WA; Chang DY; Chen BM; Lin YC; Barenholz Y; Roffler SR
ACS Nano; 2023 Mar; 17(6):5757-5772. PubMed ID: 36926834
[TBL] [Abstract][Full Text] [Related]
7. A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes.
Talkington AM; McSweeney MD; Wessler T; Rath MK; Li Z; Zhang T; Yuan H; Frank JE; Forest MG; Cao Y; Lai SK
J Control Release; 2022 Mar; 343():518-527. PubMed ID: 35066099
[TBL] [Abstract][Full Text] [Related]
8. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals.
Kozma GT; Shimizu T; Ishida T; Szebeni J
Adv Drug Deliv Rev; 2020; 154-155():163-175. PubMed ID: 32745496
[TBL] [Abstract][Full Text] [Related]
9. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
[TBL] [Abstract][Full Text] [Related]
10. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.
McSweeney MD; Wessler T; Price LSL; Ciociola EC; Herity LB; Piscitelli JA; Zamboni WC; Forest MG; Cao Y; Lai SK
J Control Release; 2018 Aug; 284():171-178. PubMed ID: 29879519
[TBL] [Abstract][Full Text] [Related]
11. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead.
Moghimi SM; Andersen AJ; Hashemi SH; Lettiero B; Ahmadvand D; Hunter AC; Andresen TL; Hamad I; Szebeni J
J Control Release; 2010 Sep; 146(2):175-81. PubMed ID: 20388529
[TBL] [Abstract][Full Text] [Related]
12. High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies.
Talkington AM; McSweeney MD; Zhang T; Li Z; Nyborg AC; LaMoreaux B; Livingston EW; Frank JE; Yuan H; Lai SK
J Control Release; 2021 Oct; 338():804-812. PubMed ID: 34481925
[TBL] [Abstract][Full Text] [Related]
13. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
14. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products.
Ibrahim M; Ramadan E; Elsadek NE; Emam SE; Shimizu T; Ando H; Ishima Y; Elgarhy OH; Sarhan HA; Hussein AK; Ishida T
J Control Release; 2022 Nov; 351():215-230. PubMed ID: 36165835
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
[TBL] [Abstract][Full Text] [Related]
16. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
[TBL] [Abstract][Full Text] [Related]
17. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
[TBL] [Abstract][Full Text] [Related]
18. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity.
Mima Y; Abu Lila AS; Shimizu T; Ukawa M; Ando H; Kurata Y; Ishida T
J Control Release; 2017 Mar; 250():20-26. PubMed ID: 28179196
[TBL] [Abstract][Full Text] [Related]
19. Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy.
Li Z; Ma A; Miller I; Starnes R; Talkington A; Stone CA; Phillips EJ; Choudhary SK; Commins SP; Lai SK
J Control Release; 2024 Feb; 366():342-348. PubMed ID: 38182056
[TBL] [Abstract][Full Text] [Related]
20. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
